Ashwin (IBD) Ananthakrishnan, Philip L. De Jager (MS), Beth Karlson, Helena Canhão, Kat, Sordo, Guergana, Stan, Peter Szolovits, Robert Plenge, Raoul Guzman, Vivian Gainer, Xia Zongqi (Neuro-rheumatology), LJ Wei, Peter Szolovits, Tianxi Cai
The PI's described how they propose to build on the experience of the RA DBP to go into further depth into the phenotypes (around RA) and drug effects/efficacy and see how far we can go with EHR-derived phenotypes. Further, we will be studying the shared and differing pathotypes across a larger range of autoimmune diseases, namely including inflammatory bowel disease and multiple sclerosis (for which we have expert representation in this DBP). We also reviewed the imperative to identify subcohorts (based on combinations of clinical and genomic stratification) that have distinguishing therapeutic efficacy and/or adverse events.
No comments:
Post a Comment